Olmesartan medoxomil: current status of its use in monotherapy.
Olmesartan medoxomil: current status of its use in monotherapy.
复制标题
Olmesartan Medoxomil：其在单一疗法中使用的现状。
DOI：
10.2147/vhrm.2006.2.4.327
复制
发表时间：
2006
影响因子：
2.9
通讯作者：
Brunner, Hans R
中科院分区：
文献类型：
--
作者：
Brunner, Hans R
奥美沙坦美多昔米是一种血管紧张素II受体拮抗剂。在对7个随机、双盲试验进行的综合分析中，奥美沙坦美多克米治疗8周在有效率、达到目标血压(BP)的患者比例以及与基线相比的平均舒张压(DBP)和收缩压(SBP)变化方面明显优于安慰剂。奥美沙坦美多克米起效快，两周后组间差异明显。该药物耐受性良好，不良反应与安慰剂相似。在2型糖尿病患者中，奥美沙坦美多昔米降低了肾血管阻力，增加了肾脏灌注量，减少了氧化应激。在几项大型随机双盲试验中，就主要终点而言，奥美沙坦20 mg的疗效显著高于推荐剂量的氯沙坦、valsartan、厄贝沙坦或坎地沙坦酯，并提供更好的24小时血压保护。奥美沙坦美多克米的疗效至少与氨氯地平、非洛地平和阿替洛尔相当，明显优于卡托普利。奥美沙坦美多克米在降低血压以外的心血管风险方面的有效性目前正在进行试验，试验涉及动脉粥样硬化或2型糖尿病的高危患者。
Olmesartan medoxomil is an angiotensin II receptor antagonist. In pooled analyses of seven randomized, double-blind trials, 8 weeks’ treatment with olmesartan medoxomil was significantly more effective than placebo in terms of the response rate, proportion of patients achieving target blood pressure (BP) and mean change from baseline in diastolic (DBP) and systolic blood pressure (SBP). Olmesartan medoxomil had a fast onset of action, with significant between-group differences evident from 2 weeks onwards. The drug was well tolerated with a similar adverse event profile to placebo. In patients with type 2 diabetes, olmesartan medoxomil reduced renal vascular resistance, increased renal perfusion, and reduced oxidative stress. In several large, randomized, double-blind trials, olmesartan medoxomil 20 mg has been shown to be significantly more effective, in terms of primary endpoints, than recommended doses of losartan, valsartan, irbesartan, or candesartan cilexetil, and to provide better 24 h BP protection. Olmesartan medoxomil was at least as effective as amlodipine, felodipine and atenolol, and significantly more effective than captopril. The efficacy of olmesartan medoxomil in reducing cardiovascular risk beyond BP reduction is currently being investigated in trials involving patients at high risk due to atherosclerosis or type 2 diabetes.